Literature DB >> 26351895

Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion.

Amanda Zimmerman1, Frederick L Locke, Josephine Emole, Marilin Rosa, Pedro Horna, Susan Hoover, Deniz Dayicioglu.   

Abstract

A woman aged 48 years presented with fevers, chills, weight loss, and night sweats. She had significant lymphadenopathy of the left neck as well as the left axilla. Her history was significant for bilateral breast augmentation with textured silicone implants more than 25 years ago. Excisional biopsy of a cervical lymph node revealed large, atypical cells positive for CD4 and CD30 and negative for Epstein-Barr virus-encoded ribonucleic acid, CD2, CD3, CD5, CD7, CD8, CD15, CD20, pan-keratin, S100, anaplastic lymphoma kinase (ALK), and paired box 5. These findings were consistent with Ann Arbor stage IIIB ALK-anaplastic large cell lymphoma (ALCL). The patient was started on 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone. She initially had no signs or symptoms of breast involvement; however, after developing seroma during the clinical course, the patient underwent capsulectomy and removal of the intact, textured silicone implants. Pathological evaluation demonstrated ALK-ALCL in the left breast capsule with cells displaying a significant degree of pleomorphism with binucleated forms and numerous mitoses. Fluorescence in situ hybridization confirmed the tumor was negative for t(2;5). She presented 8 weeks later showing evidence of recurrent systemic disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26351895     DOI: 10.1177/107327481502200317

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  5 in total

Review 1.  Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

Authors:  Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir
Journal:  Plast Surg (Oakv)       Date:  2020-05-21       Impact factor: 0.947

2.  Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.

Authors:  Kristin Richardson; Taha Alrifai; Kelly Grant-Szymanski; George J Kouris; Parameswaran Venugopal; Brett Mahon; Reem Karmali
Journal:  Mol Clin Oncol       Date:  2017-02-17

3.  Screening of a Novel Upregulated lncRNA, A2M-AS1, That Promotes Invasion and Migration and Signifies Poor Prognosis in Breast Cancer.

Authors:  Kai Fang; Hu Caixia; Zhang Xiufen; Guo Zijian; Lihua Li
Journal:  Biomed Res Int       Date:  2020-04-11       Impact factor: 3.411

Review 4.  Breast implant-associated anaplastic large cell lymphoma: a review.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Mark W Clemens; Maria C Ferrufino-Schmidt; Sergio Pina-Oviedo; Roberto N Miranda
Journal:  Mod Pathol       Date:  2018-09-11       Impact factor: 7.842

5.  Breast Implant-Associated Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature.

Authors:  Eva Berlin; Kunwar Singh; Christopher Mills; Ilan Shapira; Richard L Bakst; Manjeet Chadha
Journal:  Case Rep Hematol       Date:  2018-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.